NIH Granted Gene Therapy Patent

Article

WASHINGTON--The U.S. Patent and Trademark Office has awarded a broad patent on gene therapy to the National Institutes of Health. Six years after filing the application, NIH and its licensee, Genetic Therapy, Inc. of Gaithersburg, Maryland, can now use the patent for ex vivo human gene therapy.

WASHINGTON--The U.S. Patent and Trademark Office has awarded abroad patent on gene therapy to the National Institutes of Health.Six years after filing the application, NIH and its licensee,Genetic Therapy, Inc. of Gaithersburg, Maryland, can now use thepatent for ex vivo human gene therapy.

In this technique, human cells are manipulated in the laboratoryto express potentially therapeutic genes, which are then introducedinto a patient to treat disease. Coinventors of the techniqueare Michael Blaese, MD, and Stephen A. Rosenberg, MD, PhD, bothNIH scientists, and W. French Anderson, MD, a former NIH researchernow at the University of Southern California Norris Cancer Center.

Recent Videos
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
William Chou, MD, on Targeting Progranulin With Gene Therapy for Frontotemporal Dementia
Alexandra Collin de l’Hortet, PhD, the head of therapeutics at Epic Bio
David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI
Joshua M. Hare, MD, on Working to Address Unmet Needs in Alzheimer Disease With Lomecel-B Cell Therapy
John Finn, PhD, the chief scientific officer of Tome Biosciences
Related Content
© 2024 MJH Life Sciences

All rights reserved.